Answers are grounded in this paper and cite their sources.
Background: Anaplastic lymphoma kinase (ALK) rearrangement is a key oncogenic driver promoting the expression of ALK protein in non-small cell lung cancer (NSCLC). ALK tyrosine kinase inhibitors (TKIs) have significantly improved survival benefits. Exploring the optimal therapeutic regimens for ALK+ NSCLC patients is of crucial clinical significance. Case description: A 67-year-old woman with no history of smoking was diagnosed with locally advanced ALK+ lung adenocarcinoma (stage IIIC) at the first diagnosis. The patient was enrolled in the CROWN study and was randomized to receive lorlatinib treatment, and the re-examination 1 month later showed that the lung lesions were significantly reduced. The efficacy was PR, and the PFS had reached 72 months at the last follow-up. During the treatment, the patient tolerated well, no serious adverse events occurred, and the tumor was effectively controlled. Conclusions: Lorlatinib is an effective 1 L treatment option for patient with advanced ALK-positive NSCLC, which can bring long-term benefits to patients.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: